<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Meeting id="1562063" title="Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC)"><ConferenceName>50th American Society of Clinical Oncology Annual Meeting</ConferenceName><StartDate>2014-05-30T00:00:00Z</StartDate><EndDate>2014-06-03T00:00:00Z</EndDate><City>Chicago</City><Country>US</Country></Meeting>